216 related articles for article (PubMed ID: 24402161)
1. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma.
Ramakrishnan V; Painuly U; Kimlinger T; Haug J; Rajkumar SV; Kumar S
Leukemia; 2014 Jul; 28(7):1519-28. PubMed ID: 24402161
[TBL] [Abstract][Full Text] [Related]
2. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma.
Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S
Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845
[TBL] [Abstract][Full Text] [Related]
3. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC.
Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S
J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687
[TBL] [Abstract][Full Text] [Related]
4. A Smac-mimetic sensitizes prostate cancer cells to TRAIL-induced apoptosis via modulating both IAPs and NF-kappaB.
Dai Y; Liu M; Tang W; Li Y; Lian J; Lawrence TS; Xu L
BMC Cancer; 2009 Nov; 9():392. PubMed ID: 19895686
[TBL] [Abstract][Full Text] [Related]
5. X-linked inhibitor of apoptosis (XIAP) blocks Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis of prostate cancer cells in the presence of mitochondrial activation: sensitization by overexpression of second mitochondria-derived activator of caspase/direct IAP-binding protein with low pl (Smac/DIABLO).
Ng CP; Bonavida B
Mol Cancer Ther; 2002 Oct; 1(12):1051-8. PubMed ID: 12481428
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor‑related apoptosis‑inducing ligand as a therapeutic option in urothelial cancer cells with acquired resistance against first‑line chemotherapy.
Vallo S; Stege H; Berg M; Michaelis M; Winkelmann R; Rothweiler F; Cinatl J
Oncol Rep; 2020 Apr; 43(4):1331-1337. PubMed ID: 32020226
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous XIAP and cIAP1/2 inhibition by a dimeric SMAC mimetic AZD5582 induces apoptosis in multiple myeloma.
Kikuchi S; Sugama Y; Takada K; Kamihara Y; Wada A; Arihara Y; Nakamura H; Sato T
J Pharmacol Sci; 2024 Jan; 154(1):30-36. PubMed ID: 38081681
[TBL] [Abstract][Full Text] [Related]
8. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines.
Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923
[TBL] [Abstract][Full Text] [Related]
9. IRF-1 inhibits NF-κB activity, suppresses TRAF2 and cIAP1 and induces breast cancer cell specific growth inhibition.
Armstrong MJ; Stang MT; Liu Y; Yan J; Pizzoferrato E; Yim JH
Cancer Biol Ther; 2015; 16(7):1029-41. PubMed ID: 26011589
[TBL] [Abstract][Full Text] [Related]
10. Inhibitor of Apoptosis Protein-1 Regulates Tumor Necrosis Factor-Mediated Destruction of Intestinal Epithelial Cells.
Grabinger T; Bode KJ; Demgenski J; Seitz C; Delgado ME; Kostadinova F; Reinhold C; Etemadi N; Wilhelm S; Schweinlin M; Hänggi K; Knop J; Hauck C; Walles H; Silke J; Wajant H; Nachbur U; W Wei-Lynn W; Brunner T
Gastroenterology; 2017 Mar; 152(4):867-879. PubMed ID: 27889570
[TBL] [Abstract][Full Text] [Related]
11. The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis.
El-Mesery M; Shaker ME; Elgaml A
Exp Biol Med (Maywood); 2016 Dec; 241(18):2015-2022. PubMed ID: 27465142
[TBL] [Abstract][Full Text] [Related]
12. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells.
Lee DH; Sung KS; Bartlett DL; Kwon YT; Lee YJ
Cell Signal; 2015 Feb; 27(2):293-305. PubMed ID: 25446253
[TBL] [Abstract][Full Text] [Related]
13. LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling.
Afsahi A; Silvestri CM; Moore AE; Graham CF; Bacchiochi K; St-Jean M; Baker CL; Korneluk RG; Beug ST; LaCasse EC; Bramson JL
Front Immunol; 2023; 14():1179827. PubMed ID: 37138866
[TBL] [Abstract][Full Text] [Related]
14. (E)-2,4-Bis(p-hydroxyphenyl)-2-butenal enhanced TRAIL-induced apoptosis in ovarian cancer cells through downregulation of NF-κB/STAT3 pathway.
Cho SH; Park MH; Lee HP; Back MK; Sung HC; Chang HW; Kim JH; Jeong HS; Han SB; Hong JT
Arch Pharm Res; 2014 May; 37(5):652-61. PubMed ID: 24390815
[TBL] [Abstract][Full Text] [Related]
15. Targeting inhibitors of apoptosis in oral squamous cell carcinoma in vitro.
Scheurer MJJ; Seher A; Steinacker V; Linz C; Hartmann S; Kübler AC; Müller-Richter UDA; Brands RC
J Craniomaxillofac Surg; 2019 Oct; 47(10):1589-1599. PubMed ID: 31387829
[TBL] [Abstract][Full Text] [Related]
16. LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus-negative Head and Neck Squamous Cell Carcinoma.
Yang L; Kumar B; Shen C; Zhao S; Blakaj D; Li T; Romito M; Teknos TN; Williams TM
Mol Cancer Ther; 2019 Jun; 18(6):1025-1035. PubMed ID: 31015310
[TBL] [Abstract][Full Text] [Related]
17. Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.
Mitsiades N; Mitsiades CS; Poulaki V; Anderson KC; Treon SP
Blood; 2002 Mar; 99(6):2162-71. PubMed ID: 11877293
[TBL] [Abstract][Full Text] [Related]
18. A small molecule Smac-mimic compound induces apoptosis and sensitizes TRAIL- and etoposide-induced apoptosis in breast cancer cells.
Bockbrader KM; Tan M; Sun Y
Oncogene; 2005 Nov; 24(49):7381-8. PubMed ID: 16044155
[TBL] [Abstract][Full Text] [Related]
19. IAP antagonists induce anti-tumor immunity in multiple myeloma.
Chesi M; Mirza NN; Garbitt VM; Sharik ME; Dueck AC; Asmann YW; Akhmetzyanova I; Kosiorek HE; Calcinotto A; Riggs DL; Keane N; Ahmann GJ; Morrison KM; Fonseca R; Lacy MQ; Dingli D; Kumar SK; Ailawadhi S; Dispenzieri A; Buadi F; Gertz MA; Reeder CB; Lin Y; Chanan-Khan AA; Stewart AK; Fooksman D; Bergsagel PL
Nat Med; 2016 Dec; 22(12):1411-1420. PubMed ID: 27841872
[TBL] [Abstract][Full Text] [Related]
20. Novel second mitochondria-derived activator of caspases (Smac) mimetic compounds sensitize human leukemic cell lines to conventional chemotherapeutic drug-induced and death receptor-mediated apoptosis.
Servida F; Lecis D; Scavullo C; Drago C; Seneci P; Carlo-Stella C; Manzoni L; Polli E; Lambertenghi Deliliers G; Delia D; Onida F
Invest New Drugs; 2011 Dec; 29(6):1264-75. PubMed ID: 20614162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
